Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
travoprost intracameral implant
- Development stage
- Approved
- Lead developer
- Glaukos
- Modality
- Small Molecules
- Administration
- Intracameral, Ophthalmic
01
Overview
iDose TR is a first-of-its-kind, long-duration, anchored intracameral procedural pharmaceutical therapy for the treatment of open-angle glaucoma (OAG) or ocular hypertension (OHT). It consists of a titanium implant reservoir with a membrane controlling the sustained release of travoprost, a prostaglandin analog that increases the flow of aqueous humor out of the eye, thereby decreasing intraocular pressure. The implant is administered intracamerally through a small corneal incision and anchored into the sclera at the iridocorneal angle, providing continuous 24/7 therapeutic levels of travoprost directly inside the eye for extended periods.
- Brand names
- iDose TR
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on travoprost intracameral implant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on travoprost intracameral implant.